Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the Invesco Pharmaceuticals ETF (PJP), a passively managed exchange traded fund ...

PHRMAG represents 29 leading global biopharmaceutical research companies in the region. Dedicated to advancing innovation and ...

Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended ...

With numerous commitments made in VPAG, time will tell how transparent the government ... leavers of the predecessor scheme VPAS – AbbVie and Eli Lilly – there will be interest in whether ...

And, most ETFs are very transparent products that disclose their ... accounts for about 4.40% of total assets, followed by Abbvie Inc (ABBV) and Blackrock Inc (BLK). The top 10 holdings account ...

In another recommendation, pharmaceutical companies need to be more transparent about the way ... as a consultant or on advisory boards for AbbVie, Amgen, Bristol Myers Squibb, Celsius ...

The EU drugs regulator says Gilead Sciences’ antiviral drug remdesivir should be made available for people seriously ill with COVID-19, despite limited data on its efficacy. The EMA’s human ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...